FDA Clears the Way for Generic Versions of Transdermal Patches to Treat Chronic Pain
The Food and Drug Administration (FDA) has granted approval to Mylan Technologies, Inc., for the first generic version of Alza Corporation's Duragesic Patch (Fentanyl Transdermal System) used to treat patients suffering from severe chronic pain that cannot be managed with alternative analgesics. When applied to the skin, this patch technology delivers fentanyl, an opioid pain medication that is s...Transdermal HRT not cardioprotective in postmenopausal women with CAD
Transdermal hormone replacement therapy (HRT) does not reduce the risk of cardiac events in postmenopausal women with existing coronary artery disease (CAD). In the PHASE trial (Papworth HRT Atherosclerosis Study), researchers randomized 255 postmenopausal women with angiographically proven coronary artery disease to receive either transdermal HRT--17-beta-estradiol with or without cy...Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
Transdermal hormone replacement therapy (HRT) does not reduce the risk of cardiac events in postmenopausal women with existing coronary artery disease (CAD). In the PHASE trial (Papworth HRT Atherosclerosis Study), researchers randomized 255 postmenopausal women with angiographically proven coronary artery disease to receive either transdermal HRT--17-beta-estradiol with or without cy...Transdermal Vaccine Effective in Treating Alzheimer's Disease in Mice
University of South Florida researchers report that a novel needle-free vaccine approach// is effective and safe in clearing brain-damaging plaques from a mouse model of Alzheimer’s disease. The transdermal, or across the skin, vaccination, may offer a simpler way of preventing or treating the devastating neurodegenerative disease with less likelihood of adverse immune reactions. <br...NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., aprivately held specialty pharmaceutical company, today announcedpositive results from an initial Phase I study of NP101SmartRelief, a novel treatment for acute migraine being developedby NuPathe. NP101 combines NuPathe's SmartRelief(TM) proprietaryiontophoretic transdermal technology with sumatriptan, the mostwidely prescri...Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today that the Companyintends to initiate a Phase 1b clinical trial to demonstrate theefficacy and safety of the improved formulation of its transdermalinsulin product, TPM-02/Insulin, containing long-acting insulin.The trial is expected to commence in the second quarter of2007....